Conventional and molecular cytogenetics of ph-negative chronic myeloproliferative disorders

Myeloproliferative Disorders: Biology and Management

Volumn , Issue , 2007, Pages 51-68

  Najfeld, Vesna ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84955663826     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (86)

1. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythemia vera. Nature 2005;434:1144-11482.
2. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387-397.
3. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054-1061.
4. Sandberg EM, Wallace TA, Godeny MD, et al. JAK2 tyrosine kinase: a true JAK for all trades? Cell Biochem Biophys 2004;41:207-232.
5. Valentino L, Pierre J. JAK/STAT signal transduction: regulators and implication in hematological malignancies. Biochem Pharmacol 2006;71(6):713-721.
6. Freener EP, Rosario F, Dunn SL, et al. Tyrosine phosphorylation of JAK2 in the JH domain inhibits cytokine signaling. Mol Cell Biol 2004;24:4968-4978.
7. Skoda R, Prchal JT. Chronic myeloproliferative disorders-introduction. Semin Hematol 2005;42:181-182.
8. O’Shea JJ, Gadina M, Schreiber RD. Cytokine signaling in 2002: new surprises in the JAK/STAT pathway. Cell 2002;109(suppl.):S2121-S2131.
9. Saharinen P, Vihinen M, Silvennoinen O. Autoinhibition of JAK2 tyrosine kinase is dependent on specific regions in its pseudokinase domain. Mol Biol Cell 2003;14:1448-1459.
10. Larsen TS, Christensen JH, Hasselbalch HC, et al. The JAK2 V617 mutation involves B- and T-lymphocytes lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders. Br J Haematol 2007;136:745-751.
11. Wernig G, Mercher T, Okabe R, et al. Expression of JAK2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 2006;107:4274-4281.
12. Lacout C, Pisani DF, Tuliez M, et al. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 2006;108(5):1652-1660.
13. Najfeld V. FISHing among myeloproliferative disorders. Semin Hematol 1997;34(1):55-63.
14. Schoch C, Schnittger S, Bursch S, et al. Comparison of chromosome banding analysis, interphase and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases. Leukemia 2003;16:53-59.
15. Asimakopolous FA, Holloway TL, Nacheva EP, et al. Detection of chromosome 20q deletions in bone marrow metaphases but not peripheral blood granulocytes in patients with myeloproliferative disorders and myelodysplastic syndromes. Blood 1994;87:1561-1570.
16. Najfeld V, Montella L, Scalise A, et al. Exploring polycythemia vera with fluorescence in situ hybridization: Additional cryptic 9p is the most frequent abnormality detected. Br J Haematol 2002;119:558-566.
17. Westwood NB, Gruszka-Westwood AM, Pearson CE, et al. The incidence of trisomy 8, trisomy 9, and D20S109 deletion in polycythemia vera: An analysis of blood granulocytes using interphase fluorescence in situ hybridization. Br J Haematol 2000;110:839-846.
18. Reilly JT. Cytogenetic and molecular genetic abnormalities in agnogenic myeloid metaplasia. Semin Oncol 2005;32:359-364.
19. Campbell PJ, Griesshammer M, Dohner K, et al. V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. Blood 2006;107:2098-2100.
20. Swolin B, Weinfeld A, Westin J. A prospective long-term cytogenetics study in Polycythemia vera in relation to treatment and clinical course. Blood 1988;72: 386-395.
21. Zhang W, Berkofsky-Fessler W, Levine R, et al. High-resolution SNP arrays and correlation with expression arrays identify novel genomic aberrations and potentional disease genes in polycythemia vera and other myeloproliferative disorders. Blood 2006;108(11):111a (Abstract 359).
22. Al-Assar O, Ul-Hassan A, Browm R, et al. Gains of 9p are common genomic aberrations in idiopathic myelofibrosis: a comparative genomic hybridization study. Br J Haematol 2005;129:66-71.
23. Sambani C, La Starza R, Pierini V, et al. Leukemic recombinations involving heterochromatin in myeloproliferative disorders with t(1;9). Cancer Genet Cytogenet 2005;162:45-49.
24. Chen Z, Notohamiprodjom M, Guan X-Y, et al. Gain of 9p in the pathogenesis of polycythemia vera. Genes Chromosomes Cancer 1998;22:321-324.
25. Kralovics R, Guan Y, Prchal JT. Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera. Exp Hematol 2002;30:229-236.
26. Lacronique V, Boureux A, Valle VD, et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 1997;278(5341):1309-1312.
27. Griesinger F, Henning H, Hillmer F, et al. A BCR-JAK2 fusion gene as a result of a t(9;22)(p24;q2) translocation in a patient with a clinically typical chronic myelogenous leukemia. Genes Chromosomes Cancer 2005;44:329-333.
28. Reiter A, Walz C, Watmore A, et al. The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK. Cancer Res 2005;65(7): 2662-2667.
29. Adelaide J, Perot C, Gelsi-Bojer V, et al. A t(8;9) translocation with PCM1-JAK2 fusion in a patient with T-cell lymphoma. Leukemia 2006;3:536-537.
30. Najfeld V, Berkofsky-Fessler W, Cozza A. FISH studies provide evidence that JAK2, via a myriad of mechanisms not limited to point mutations, has gain of function in polycythemia vera (PV) and myelodysplasia (MDS). Blood 2006;108(11): 763a (Abstract 2637).
31. Roulston D, Espinoza R, 3rd, Stoffel M, et al. Molecular genetics of myeloid leukemia: Identification of the commonly deleted segment of chromosome 20 Blood 1993;82:3424-3429.
32. Bench AJ, Nacheva EP, Hood TL, et al. Chromosome 20 deletions in myeloid malignancies: reduction of the common deleted region, generation of a PAC/BAC contig and identification of candidate genes. Oncogene 2000;19:3902-3913.
33. Bench AJ, Cross NCP, Nacheva EP, et al. Myeloproliferative disorders. Best Pract Res Clin Haematol 2001;14:531-551.
34. Andrieux J, Demory JL. Karyotype and molecular cytogenetics studies in polycythemia vera. Curr Hematol Rep 2005;4:224-229.
35. Raskind WH, Steinmann L, Najfeld V. Clonal development of myeloproliferative disorders: Clues to hematopoietic differentiation and multistep pathogenesis of cancer. Leukemia 1998;12:108-116.
36. Kaye FJ, Najfeld V, Singer J, et al. Confirming evidence for the clonal development and stem cell origin of Philadelphia chromosome-negative chronic myelogenous leukemia. Am J Hematol 1984;17:93-96.
37. Tefferi A, Dingli D, Li C-Y, et al. Prognostic diversity among cytogenetics abnormalities in myelofibrosis with myeloid metaplasia. Cancer 2005;104:1656-1660.
38. Strasser-Weippl K, Steurer M, Kees M, et al. Prognostic relevance of cytogenetics determined by fluorescent in situ hybridization in patients having myelofibrosis with myeloid metaplasia. Cancer 2006;107:2801-2806.
39. Campbell LJ, Garson OM. The prognostic significance of deletion of the long arm of chromosome 20 in myeloid disorders. Leukemia 1994;8:67-71.
40. Greenberg P, Cox C, LeBeau MM, et al. International Scoring System for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-2088.
41. Gribble SM, Reid AG, Bench AJ, et al. Molecular cytogenetics of polycythemia vera: Lack of occult rearrangements detectable by 20q LSP screening, CGH, and M-FISH. Leukemia 2003;17:1419-1421.
42. Busson M, Romana S, Khac FN, et al. Cryptic translocations involving chromosome 20 in polycythemia vera. Ann Genet 2004;47:365-371.
43. Kralovics R, Teo SS, Li S, et al. Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood 2006;108:1377-1380.
44. Price CM, Kufer EJ, Colman SM, et al. Simultaneous genotypic and immunopheno-typing analysis of interphase cells using dual color fluorescence: A demonstration of lineage involvement in polycythemia vera. Blood 1992;80:1033-1038.
45. Diez Martin JL, Graham DL, Petitt RM, et al. Chromosome studies in 104 patients with polycythemia vera. Mayo Clin Proc 1991;66:287-299.
46. Tefferi A, Messa RA, Schroeder G, et al. Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia. Br J Haematol 2001;113:763-771.
47. Najfeld V, Scalise A, Kalir D, et al. Trisomy of gene(s) on chromosome 1 are frequently involved in recurrent rearrangements among patients with Ph-negative myelo-proliferative and myelodysplastic disorders. Blood 2003;102(11):660a (Abstract 2445).
48. Hsiao H-H, Ito Y, Sashida G, et al. De novo appearance of der(1;7)(q10;p10) is associated with leukemic transformation and unfavorable prognosis in essential thrombocythemia. Leuk Res 2005;29:1247-1252.
49. Andreaux J, Demory JL, Caulier ML, et al. Karyotypic abnormalities in myelofibrosis following polycythemia vera. Cancer Genet Cytogenet 2003;140:118-123.
50. Tanaka K, Arif M, Eguchi M, et al. Frequent allelic loss of the RB, D13S319 and D13S25 locus in myeloid malignancies with deletion/translocation of 13q14 of chro- mosome 13 but not in lymphoid malignancies. Leukemia 1999;13:1367-1373.
51. http://atlasgeneticsoncology.org/Anomalies/del7qID1093.html
52. Strasser-Weippl K, Steurer M, Kees M, et al. Chromosome 7 deletions are associated with unfavorable prognosis in myelofibrosis with myeloid metaplasia. Blood 2005;105:41-116.
53. Messa RA, Li C-Y, Ketterling RP, et al. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood 2005;105(3):973-977.
54. Andrieux J, Demory JL, Morel P, et al. Frequency of structural abnormalities of the long arms of chromosome 12 in myelofibrosis with myeloid metaplasia. Cancer Genet Cytogenet 2002;137:68-71.
55. Przepiorka D, Bryant E, Kidd P. Idiopathic myelofibrosis in blast transformation with 4;12 and 5;12 translocation and 7q deletion. Cancer Genet Cytogenet 1988;30(1): 139-144.
56. Borrego S, Antinolo G, Martin-Noya K, et al. Translocation (8;12) in a patient with agnogenic myeloid metaplasia. Cancer Genet Cytogenet 1993;71(2):183-184.
57. Huret JL, Brizard A, Briualt S, et al. Two additional cases of inversion 12 in human malignancies. Cancer Genet Cytogenet 1988;32(2):309-311.
58. Teferii A, Meyer RG, Wyatt WA, et al. Comparison of peripheral blood interphase cytogenetics with bone marrow karyotype analysis in myelofibrosis with myeloid metaplasia. Br J Haematol 2001;115:316-319.
59. Djordjevic V, Dencic-Fekete M, Jovanovic J, et al. Cytogenetics of agnogenic myeloid metaplasia: a study of 61 patients. Cancer Genet Cytogenet 2007;173:57-62.
60. Golub TR, Barker GF, Lovett M, et al. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t (5;12) chromosomal translocation. Cell 1994;77:307-316.
61. Xiao S, Nalabolu SR, Aster JC, et al. FGFR1 is fused with a novel zinc-finger gene ZNF198 in the t(8;13) leukemia/lymphoma syndrome. Nat Genet 1998;18:84-87.
62. Cools J, Deangelo DJ, Gotlib J, et al. A tyrosine kinase created by a fusion of the PDGFRA and FIP1L! genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003;348:1201-1214.
63. De Keersmaecker K, Cools J. Chronic myeloproliferative disorders: a tyrosine kinase tale. Leukemia 2006;20:200-205.
64. Pellagatti A, Vetrie D, Langford CF, et al. Gene expression profiling in polycythemia vera using cDNA microarray technology. Cancer Res 2003;63(14):3940-3944.
65. Steidl U, Schroeder T, Steidel C, et al. Distinct gene expression pattern of malignant hematopoietic stem and progenitor cells in polycythemia vera. Ann NY Acad Sci 2005;1044:94-108.
66. Berkofsky-Fessler WD. Transcriptional Profiling in Polycythemia Vera, V617 JAK2 Expressing Hematopoietic Progenitor Cells, and Other Hematological Malignancies. Ph.D. dissertation, Mount Sinai School of Medicine, 2006.
67. Goertler PS, Kreutz C, Donauer J, et al. Gene expression profiling in polycythemia vera: overexpression of transcription factorNF-E. Br J Haematol 2005;129: 138-150.
68. Di Ianni M, Moretti L, Del Papa B, et al. Chronic myeloproliferative disorders: the bone marrow stromal component is not involved in the malignant clone. Leukemia 2007;21:377-378.
69. Campbell PJ, Scott LM, Buck G, et al. Definition of subtypes of essential thrombo-cythaemia and relation to polycythemia vera based on JAK2V617F mutation status: a prospective study. Lancet 2005;306:1945-1953.
70. Mercher T, Weing G, Moore SA, et al. JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model. Blood 2006;108:2770-2779.
71. Ihle JN, Gilliland DG. JAK2: normal function and role in hematopoietic disorders. Curr Opin Genet Dev 2007;17:8-14.
72. Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007;356:459-468.
73. Malinge S, Ben-Abdelali R, Settegrana C, et al. Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia. Blood 2007;109:2202-2204.
74. Nussenzveig RH, Swierczek SI, Jelinek J, et al. Polycythemia vera is not initiated by JAK2V617F mutation. Experimental Hematology 2007;35:32-38.
75. Campbell PJ, Baxter EJ, Beer PA, et al. Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation. Blood 2006;108:3548-3555.
76. Theocharides A, Boissinot M, Girdon F, et al. Leukemic blasts in transformed JAK2-V617F positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood 2007;110:375-379.
77. Vizmanos JL, Ormazabal C, Larrayoz MJ, et al. JAK2 V617F mutation in classic chronic myeloproliferative diseases: a report on a series of 349 patients. Leukemia 2006;20:534-535.
78. Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med 2006; 355:2452-2466.
79. Tefferi A, Barosi G, Messa RA, et al. International working group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for myelofibrosis research and treatment IIWG-MRT. Blood 2006;108:1497-1503.
80. Finazzi G, Harrison C. Essential thrombocythemia. Semin Hematol 2005;42(4): 230-238.
81. Rege-Cambrin G, Mecucci C, Tricot G, et al. A chromosomal profile in polycythemia vera. Cancer Genet Cytogenet 1987;24:233-245.
82. Zamora L, Espinet B, Florensa L, et al. Is fluoresnce in situ hybridization a useful method in diagnosis of polycythemia vera patients? Cancer Genet Cytogenet 2004;151:139-145.
83. Bacher U, Haferlach T, Kern W, et al. Conventional cytogenetics of myeloproliferative diseases other than CML contributes valid information. Ann Hematol 2005;84: 250-257.
84. Dupriez B, Morel P, Demory JL, et al. Prognostic factors in agnogenic myeloid metaplasia: A report of 195 cases with a new scoring system. Blood 1996;88: 1013-1018.
85. Reilly JT. Idiopathic myelofibrosis; pathogenesis, natural history, and management. Blood Rev 1997;11:233-242.
86. Swolin B, Safai-Kutti S, Angehm E, et al. No increased frequency of trisomies 8 and 9 by fluorescence in situ hybridization in untreated patients with essenthial thrombocythemia. Cancer Genet Cytogenet 2001;126:56-59.